![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Wuerstlein, R.; Kates, R.; Gluz, O.; Grischke, E. M.; Schem, C.; Thill, M.; Hasmüller, S.; Köhler, A.; Otremba, B.; Griesinger, F.; Schindlbeck, C.; Trojan, A.; Otto, F.; Knauer, M.; Pusch, R. und Harbeck, N.
(2019):
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
In: Breast Cancer Research and Treatment, Bd. 175, Nr. 2: S. 389-399
Witzel, I.; Laakmann, E.; Weide, R.; Neunhoeffer, T.; Park-Simon, T. -J.; Schmidt, M.; Fasching, P. A.; Hesse, T.; Polasik, A.; Mohrmann, S.; Wuerschmidt, F.; Schem, C.; Bechtner, C.; Würstlein, R.; Fehm, T.; Moebus, V.; Burchardi, N.; Loibl, S. und Müller, V.
(2018):
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
In: European Journal of Cancer, Bd. 102: S. 1-9
Würstlein, R.; Gluz, O.; Kates, R.; Persoon, M.; Wasmayr, M.; Knauer, M.; Koplmüller, R.; Grischke, E.-M.; Schem, C.; Thill, M.; Hasmüller, S.; Griesinger, F.; Köhler, A.; Otremba, B.; Schindlbeck, C.; Reimer, T.; Krauter, J.; Tome, O.; Otto, F.; Friedrichs, K.; Albert, U.-S.; Gebauer, G.; Nitz, U. und Harbeck, N.
(2017):
Results of multigene assay (MammaPrint (R)) and molecular subtyping (BluePrint (R)) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study.
In: Cancer Research, Bd. 77
Mackelenberg, M. van; Denkert, C.; Nekljudova, V.; Karn, T.; Schem, C.; Marme, F.; Stickeler, E.; Jackisch, C.; Hanusch, C.; Huober, J.; Fasching, P.; Blohmer, J.-U.; Kummel, S.; Müller, V.; Schneeweiss, A.; Untch, M.; Minckwitz, G. von; Weber, K. und Loibl, S.
(2017):
Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
In: Cancer Research, Bd. 77
Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, J.; Kates, R. E.; Pelz, E. und Harbeck, N.
(2016):
Prosigna®(R) results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study.
In: Cancer Research, Bd. 76
Fasching, P. A.; Loibl, S.; Eidtmann, H.; Tesch, H.; Untch, M.; Hilfrich, J.; Schem, C.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T. N.; Huober, J.; Liedtke, C.; Müller, V.; Nekljudova, V.; Weber, K.; Rack, B.; Rübner, M.; Wang, L.; Ingle, J. N.; Weinshilboum, R. M.; Minckwitz, G. von und Couch, F.
(2016):
BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study.
In: Cancer Research, Bd. 76
Wuerstlein, R.; Sotlar, K.; Gluz, O.; Hofmann, D.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Morel, P.; Cowens, W.; Hornberger, A.; Kates, R. E.; Pelz, E. und Harbeck, N.
(2016):
Prosigna® results impact on adjuvant decision making in early breast cancer (EBC): Final analysis of the prospective WSG study.
In: Oncology Research and Treatment, Bd. 39: S. 49
Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; Schumann, R. von; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E. und Harbeck, N.
(2016):
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
In: Current Medical Research and Opinion, Bd. 32, Nr. 7: S. 1217-1224
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185